TNFRSF17: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD

It's the GeneMedi's summary page for Target/Biomarker Introduction of TNFRSF17. The page also collects GeneMedi's different modalities and formats products for TNFRSF17 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the TNFRSF17 target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13B/TALL-1/BAFF), and to lead to NF-kappaB and MAPK8/JNK activation. This receptor also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. [provided by RefSeq, Jul 2008]

Pre-made TNFRSF17-specific INN-index biosimilar (antibody&conjugates)-motacabtagene lurevgedleucel, belantamab mafodotin, idecabtagene vicleucel, Elranatamab, Pavurutamab, Belantamab, Pacanalotamab, ciltacabtagene autoleucel, Alnuctamab, zevorcabtagene autoleucel, Teclistamab, orvacabtagene autoleucel

Anti-TNFRSF17 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cat No.	Products Name (INN Index)	INN Name	Previous Name	Target	Format	Order
GMP-Bios-INN-919		motacabtagene lurevgedleucel		TNFRSF17	Engineering T cell
GMP-Bios-INN-752	Pre-Made Belantamab Mafodotin Biosimilar, Whole Mab Adc, Anti-Tnfrsf17 Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A therapeutic antibody Drug Conjugate	belantamab mafodotin		TNFRSF17	Whole mAb ADC
GMP-Bios-INN-860		idecabtagene vicleucel		TNFRSF17	Engineering T cell
GMP-Bios-ab-663	Pre-Made Elranatamab biosimilar, Whole mAb, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody	Elranatamab		TNFRSF17;CD3E	Bispecific Whole mAb
GMP-Bios-ab-433	Pre-Made Pavurutamab biosimilar, Bispecific scFv, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody	Pavurutamab		TNFRSF17;CD3E	Bispecific scFv
GMP-Bios-ab-055	Pre-Made Belantamab biosimilar, Whole mAb ADC, Anti-TNFRSF17 Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A therapeutic antibody	Belantamab		TNFRSF17	Whole mAb ADC
GMP-Bios-ab-421	Pre-Made Pacanalotamab biosimilar, Bispecific scFv, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody	Pacanalotamab		TNFRSF17;CD3E	Bispecific scFv
GMP-Bios-INN-779		ciltacabtagene autoleucel		TNFRSF17	Engineering T cell
GMP-Bios-ab-018	Pre-Made Alnuctamab biosimilar, Bispecific mAb with Domain Crossover, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody	Alnuctamab		TNFRSF17;CD3E	Bispecific mAb with Domain Crossover
GMP-Bios-INN-1056		zevorcabtagene autoleucel		TNFRSF17	Engineering T cell
GMP-Bios-ab-557	Pre-Made Teclistamab biosimilar, Bispecific mAb, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody	Teclistamab		TNFRSF17;CD3E	Bispecific mAb
GMP-Bios-INN-942		orvacabtagene autoleucel		TNFRSF17	Engineering T cell

Pre-made anti-TNFRSF17 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-TNFRSF17 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-TNFRSF17 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cat No.	Antibody Name	Format	Classified by tag	Order
GM-Tg-hg-T66693-Ab	Anti-TNFRSF17 monoclonal antibody	mab	Biofunctional antibody, Therapeutics Target antibody, Cytokine antibody